“ A Phase III, Randomized, Non-Inferiority Study Comparing the Efficacy and Safety of Biosimilar Filgrastim Versus Originator Filgrastim for Chemotherapy-Induced Neutropenia in Breast Cancer Patients ”. Clinics 71, no. 10 (October 1, 2016): 586–592. Accessed May 18, 2024. https://revistas.usp.br/clinics/article/view/122233.